Kymera Therapeutics stock
KYMRNASDAQKymera Therapeutics, Inc., HealthcareISIN US5015751044
45Score 45 out of 100, Weak
Price and trend
87 / 100
Price history
+100% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 8.4% below its 52-week high. Largest decline in 6 years: 88% (December 2020 to October 2023).
Chart figures for advanced users
- SMA 50$116.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$99.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$63.53
- The lowest closing price of the last twelve months.
- Resistance$138.86
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kymera Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $12.73B, is number 26 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $39.2M (down 16.7% year on year) and a loss of $311.4M.
- MEQIRI Score 45 out of 100 (Weak): rank 457 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $971.21M, financial debt $76.6M.Stability 54
Weaknesses
- DilutionShare count up 89% since 2020.Capital allocation 18
- Loss-makingLoss of $349.47M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$288.89M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 16.7% on the prior year. Revenue turned from negative at the start of the period to positive ($39.2M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −891%, net −794%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 29 Oct 2026EPS reported −$1.32 (expected −$1.26)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.95−2.4%
- Revenue
- $100.48M−4.1%
- Earnings per share
- −$5.13−0.5%
- Revenue
- $42.03M+8.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +3.4%Kymera confirms its existing timelines: KT-621 Phase IIb atopic dermatitis data by year-end, asthma data in late 2027, and no additional collaboration revenue expected for 2026.
“We also expect to fund the KT-621 Phase III studies in AD in the initial stages of the Phase III development in asthma within our current runway.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $392.6M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Mainolfi NelloSale
1 Oct 2026, Chief Executive Officer
- Shares
- 30,000
- Price
- $113.80
- Value
- $3.41M
- Adams BrianSale
4 Sept 2026, Chief Legal Officer
- Shares
- 6,371
- Price
- $116.83
- Value
- $744,297
- Mainolfi NelloSale
7 Jul 2026, Chief Executive Officer
- Shares
- 50,000
- Price
- $119.00
- Value
- $5.95M
Show 20 more
- Goodman NoahSale
1 Jul 2026, Chief Business Officer
- Shares
- 3,389
- Price
- $114.29
- Value
- $387,329
- Mainolfi NelloSale
1 Jul 2026, Chief Executive Officer
- Shares
- 80,000
- Price
- $115.29
- Value
- $9.22M
- Jacobs Bruce N.Sale
30 Jun 2026, Chief Financial Officer
- Shares
- 77,109
- Price
- $114.96
- Value
- $8.86M
- Booth BruceSale
29 Jun 2026, Board
- Shares
- 76,650
- Price
- $108.05
- Value
- $8.28M
- Booth BruceSale
29 Jun 2026, Board
- Shares
- 4,283
- Price
- $109.48
- Value
- $468,909
- Booth BruceSale
29 Jun 2026, Board
- Shares
- 3,872
- Price
- $107.33
- Value
- $415,568
- Booth BruceSale
26 Jun 2026, Board
- Shares
- 467,878
- Price
- $110.29
- Value
- $51.6M
- Bvf Partners L P/ilSale
26 Jun 2026, Board
- Shares
- 1,630,658
- Price
- $106.50
- Value
- $173.67M
- Booth BruceSale
25 Jun 2026, Board
- Shares
- 285,684
- Price
- $121.86
- Value
- $34.81M
- Booth BruceSale
25 Jun 2026, Board
- Shares
- 262,637
- Price
- $115.39
- Value
- $30.31M
- Goodman NoahSale
25 Jun 2026, Chief Business Officer
- Shares
- 5,000
- Price
- $114.00
- Value
- $570,000
- Booth BruceSale
24 Jun 2026, Board
- Shares
- 134,720
- Price
- $100.51
- Value
- $13.54M
- Booth BruceSale
23 Jun 2026, Board
- Shares
- 1,408
- Price
- $99.98
- Value
- $140,772
- Booth BruceSale
22 Jun 2026, Board
- Shares
- 31,798
- Price
- $103.75
- Value
- $3.3M
- Booth BruceSale
22 Jun 2026, Board
- Shares
- 246,330
- Price
- $98.52
- Value
- $24.27M
- Goodman NoahSale
22 Jun 2026, Chief Business Officer
- Shares
- 2,500
- Price
- $99.00
- Value
- $247,500
- Booth BruceSale
18 Jun 2026, Board
- Shares
- 115,056
- Price
- $91.01
- Value
- $10.47M
- Booth BruceSale
17 Jun 2026, Board
- Shares
- 116,812
- Price
- $90.34
- Value
- $10.55M
- Chadwick Jeremy GSale
27 May 2026, Chief Operating Officer
- Shares
- 4,279
- Price
- $81.58
- Value
- $349,096
- Chadwick Jeremy GSale
26 May 2026, Chief Operating Officer
- Shares
- 12,905
- Price
- $79.36
- Value
- $1.02M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Kymera Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Neurocrine BiosciencesNBIX $17.15B77
- Jazz PharmaceuticalsJAZZ $15.43B66
- BridgeBio PharmaBBIO $15.23B49
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.9B49
- Madrigal PharmaceuticalsMDGL $12.44B33
- Pharmaron Beijing300759.SZ $12.15B58
- Summit TherapeuticsSMMT $12.03B34
- Financière de TubizeTUB.BR $11.94B50
ETFs that hold Kymera Therapeutics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.70% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.29% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.28% | 0.30% | €4.28B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.11% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.06% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.10% | €395.74M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.02% | 0.25% | €178.55M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.